Zobrazeno 1 - 10
of 163
pro vyhledávání: '"Steven T. Rosen"'
Autor:
Flavia Pichiorri, Ralf Buettner, Shu Tao, Stephen J. Forman, Michael Rosenzweig, Myo Htut, Amrita Krishnan, Tim Synold, Ni-Chun Tsai, Xiwei Wu, Arnab Chowdhury, Steven T. Rosen, Joycelynne Palmer, Samantha N. Hammond, Nitya Nathwani, James F. Sanchez, Lupe Duarte, Chatchada Karanes, Firoozeh Sahebi
Publikováno v:
Leuk Lymphoma
The inexpensive, well-tolerated, immunomodulatory agent leflunomide, used extensively for the treatment of rheumatoid arthritis, has been shown to produce significant activity against multiple myeloma (MM) in pre-clinical studies. We conducted a phas
Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome
Autor:
Jasmine Zain, Farah Abdulla, Steven T. Rosen, X. Martinez, Cosimo Di Raimondo, Christiane Querfeld
Publikováno v:
Best Pract Res Clin Haematol
Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of cutaneous lymphoma, accounting for approximately 60% of cutaneous T-cell lymphomas. Diagnosis requires correlation of clinical, histologic, and molecular features. A multitu
Autor:
Jasmine Zain, Nicholas A. Trum, X. Martinez, Farah Abdulla, Vishwas Parekh, Michelle Afkhami, Christiane Querfeld, Steven T. Rosen, Charles L. Bennett, Kenneth R. Carson
Publikováno v:
Br J Dermatol
Summary Background Mogamulizumab is a humanized antibody against chemokine receptor type 4. It was recently approved by the US Food and Drug Administration for relapsed or refractory mycosis fungoides (MF) and Sézary syndrome (SS). The most commonly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e57c920c869144130c2117daf72cae9
https://europepmc.org/articles/PMC8738116/
https://europepmc.org/articles/PMC8738116/
Autor:
Varsha Gandhi, Xiwei Wu, Corey Morales, Ralf Buettner, Vinod Pullarkat, Guido Marcucci, Steven T. Rosen, Le Xuan Truong Nguyen, Dinh Hoa Hoang, Servando Hernandez Vargas, Lisa S. Chen, Min Hsuan Chen
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-16 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-16 (2021)
Background BCL‐2 inhibition through venetoclax (VEN) targets acute myeloid leukemia (AML) blast cells and leukemic stem cells (LSCs). Although VEN-containing regimens yield 60–70% clinical response rates, the vast majority of patients inevitably
Autor:
Matthew Mei, Stephen J. Forman, Robert T. Chen, L. Elizabeth Budde, Liana Nikolaenko, Saro H. Armenian, Larry W. Kwak, Lacolle Peters, Leslie Popplewell, Steven T. Rosen, Alex F. Herrera, Shari Daniels, Lu Chen, Neena Kennedy
Publikováno v:
Blood. 138:234-234
Introduction: Despite a high response rate to PD1 blockade in patients (pts) with relapsed/refractory (RR) Hodgkin lymphoma (HL), the complete response (CR) rate is low and most patients will progress. Pts who are refractory to PD1 blockade have limi
Autor:
Navshina Shekh, Kate Murray, Tanya Siddiqi, Pamela Clay, Steven Coutre, Alexandra Muir, Steven T. Rosen
Publikováno v:
Blood. 138:3754-3754
Introduction: Ibr and ven are 1 st generation BTK and BCL2 inhibitors respectively that are approved for use in patients with CLL. They are both oral agents that have been shown to work synergistically together with no unexpected toxicities beyond wh
Autor:
Jasmine Zain, Jonathan E. Brammer, Ranjit Nair, Lacolle Peters, Matthew Mei, Lu Chen, Larry W. Kwak, Alex F. Herrera, Kerry J. Savage, Steven T. Rosen, Leslie Popplewell, Lori A. Leslie, Chitra Hosing, Tatyana Feldman, Stephen J. Forman, Swaminathan P. Iyer, Lihua E. Budde
Publikováno v:
Blood. 138:133-133
Introduction: Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of lymphomas associated with poor outcomes following anthracycline-based chemotherapy, even when consolidative autologous stem cell transplantation (ASCT) is used. CD30 expres
Autor:
Lihua E. Budde, Jasmine Zain, Leslie Popplewell, Matthew Mei, Robert T. Chen, Larry W. Kwak, Liana Nikolaenko, Alex F. Herrera, Tanya Siddiqi, Lu Chen, Steven T. Rosen
Publikováno v:
Transplantation and Cellular Therapy. 27:S47-S48
Autor:
Estella Barrios, Joycelynne Palmer, X. Martinez, Arnab Chowdhury, Matthew Loscalzo, Steven T. Rosen, Farah Abdulla, Jasmine Zain, Tracey Stiller, Christiane Querfeld
Publikováno v:
Support Care Cancer
PURPOSE: Cutaneous lymphomas (CLs) are a group of rare, potentially disfiguring and disabling cancers that can have a significant impact on quality of life (QoL). While previous studies have shown that mycosis fungoides (MF) and Sézary syndrome (SS)
Autor:
Christiane Querfeld, Jasmine Zain, Joo Y. Song, Vishwas Parekh, Steven T. Rosen, X. Martinez, Farah Abdulla, Cosimo Di Raimondo
Publikováno v:
Current hematologic malignancy reports. 15(4)
Primary cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ LPDs) are the second most common cutaneous lymphomas after mycosis fungoides and Sezary syndrome. They include primary cutaneous anaplastic large cell lymphoma (pcALCL), lymphomatoid